Announcements Trials
Browse Landscape

Phase

Phase 1 24Phase 2 23Phase 3 7Phase 1/2 5Phase EARLY_PHASE1 2Phase 4 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Neoplasms 1Melanoma 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Cisplatin 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × Vemurafenib × Clear all
NCT01739764 2021-01-07

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Hoffmann-La Roche

Phase 4 Completed
215 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT01898585 2020-01-07

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 4 Completed
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡